These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10991964)

  • 1. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
    Jiménez W; Gal CS; Ros J; Cano C; Cejudo P; Morales-Ruiz M; Arroyo V; Pascal M; Rivera F; Maffrand JP; Rodés J
    J Pharmacol Exp Ther; 2000 Oct; 295(1):83-90. PubMed ID: 10991964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.
    Ros J; Fernández-Varo G; Muñoz-Luque J; Arroyo V; Rodés J; Gunnet JW; Demarest KT; Jiménez W
    Br J Pharmacol; 2005 Nov; 146(5):654-61. PubMed ID: 16113688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist.
    Serradeil-Le Gal C
    Cardiovasc Drug Rev; 2001; 19(3):201-14. PubMed ID: 11607038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
    Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
    Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
    Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
    Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
    Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
    Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
    Ferguson JW; Therapondos G; Newby DE; Hayes PC
    Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
    Fernández-Varo G; Ros J; Cejudo-Martín P; Cano C; Arroyo V; Rivera F; Rodés J; Jiménez W
    J Hepatol; 2003 Jun; 38(6):755-61. PubMed ID: 12763368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G
    J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal water handling in rats with decompensated liver cirrhosis.
    Jonassen TE; Christensen S; Kwon TH; Langhoff S; Salling N; Nielsen S
    Am J Physiol Renal Physiol; 2000 Dec; 279(6):F1101-9. PubMed ID: 11097629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.